JP2019517548A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517548A5
JP2019517548A5 JP2018564288A JP2018564288A JP2019517548A5 JP 2019517548 A5 JP2019517548 A5 JP 2019517548A5 JP 2018564288 A JP2018564288 A JP 2018564288A JP 2018564288 A JP2018564288 A JP 2018564288A JP 2019517548 A5 JP2019517548 A5 JP 2019517548A5
Authority
JP
Japan
Prior art keywords
pyrimidin
methyl
diazaspiro
fluoro
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018564288A
Other languages
English (en)
Japanese (ja)
Other versions
JP7007302B2 (ja
JP2019517548A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/036506 external-priority patent/WO2017214367A1/en
Publication of JP2019517548A publication Critical patent/JP2019517548A/ja
Publication of JP2019517548A5 publication Critical patent/JP2019517548A5/ja
Priority to JP2022000946A priority Critical patent/JP7461390B2/ja
Application granted granted Critical
Publication of JP7007302B2 publication Critical patent/JP7007302B2/ja
Priority to JP2024000278A priority patent/JP2024045176A/ja
Priority to JP2025083421A priority patent/JP2025113339A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018564288A 2016-06-10 2017-06-08 メニン-mll相互作用の阻害剤 Active JP7007302B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022000946A JP7461390B2 (ja) 2016-06-10 2022-01-06 メニン-mll相互作用の阻害剤
JP2024000278A JP2024045176A (ja) 2016-06-10 2024-01-04 メニン-mll相互作用の阻害剤
JP2025083421A JP2025113339A (ja) 2016-06-10 2025-05-19 メニン-mll相互作用の阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348496P 2016-06-10 2016-06-10
US62/348,496 2016-06-10
PCT/US2017/036506 WO2017214367A1 (en) 2016-06-10 2017-06-08 Inhibitors of the menin-mll interaction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022000946A Division JP7461390B2 (ja) 2016-06-10 2022-01-06 メニン-mll相互作用の阻害剤

Publications (3)

Publication Number Publication Date
JP2019517548A JP2019517548A (ja) 2019-06-24
JP2019517548A5 true JP2019517548A5 (enExample) 2020-07-27
JP7007302B2 JP7007302B2 (ja) 2022-01-24

Family

ID=59325631

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018564288A Active JP7007302B2 (ja) 2016-06-10 2017-06-08 メニン-mll相互作用の阻害剤
JP2022000946A Active JP7461390B2 (ja) 2016-06-10 2022-01-06 メニン-mll相互作用の阻害剤
JP2024000278A Pending JP2024045176A (ja) 2016-06-10 2024-01-04 メニン-mll相互作用の阻害剤
JP2025083421A Pending JP2025113339A (ja) 2016-06-10 2025-05-19 メニン-mll相互作用の阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022000946A Active JP7461390B2 (ja) 2016-06-10 2022-01-06 メニン-mll相互作用の阻害剤
JP2024000278A Pending JP2024045176A (ja) 2016-06-10 2024-01-04 メニン-mll相互作用の阻害剤
JP2025083421A Pending JP2025113339A (ja) 2016-06-10 2025-05-19 メニン-mll相互作用の阻害剤

Country Status (21)

Country Link
US (4) US10683302B2 (enExample)
EP (2) EP3805215A1 (enExample)
JP (4) JP7007302B2 (enExample)
KR (3) KR102436430B1 (enExample)
CN (1) CN109743875B (enExample)
AU (3) AU2017278950B2 (enExample)
BR (1) BR122024002146A2 (enExample)
CA (2) CA3024180A1 (enExample)
CY (1) CY1124834T1 (enExample)
DK (1) DK3468966T3 (enExample)
ES (1) ES2831084T3 (enExample)
HR (1) HRP20201771T1 (enExample)
HU (1) HUE051451T2 (enExample)
IL (4) IL298381B2 (enExample)
LT (1) LT3468966T (enExample)
MX (3) MX381228B (enExample)
PL (1) PL3468966T3 (enExample)
PT (1) PT3468966T (enExample)
SI (1) SI3468966T1 (enExample)
WO (1) WO2017214367A1 (enExample)
ZA (1) ZA201900150B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制menin及mll蛋白之交互作用的方法及組合物
AU2017212572A1 (en) 2016-01-26 2018-08-23 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
ES2831084T3 (es) * 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
AU2017326487B2 (en) 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
EP3600313A4 (en) 2017-03-31 2020-09-23 The Regents of The University of Michigan PIPERIDINES AS COVALENT MENINE INHIBITORS
CA3059675A1 (en) 2017-04-10 2018-10-18 Mitsui Chemicals Agro, Inc. Pyridone compounds and agricultural and horticultural fungicides comprising the same as active ingredients
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP7307729B2 (ja) * 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll相互作用のエキソ-アザスピロ阻害剤
CN112105621B (zh) 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
TWI815954B (zh) 2018-08-27 2023-09-21 日商住友製藥股份有限公司 光學活性氮雜雙環衍生物
CA3116141C (en) 2018-12-06 2023-09-05 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
WO2020114474A1 (zh) * 2018-12-06 2020-06-11 苏州信诺维医药科技有限公司 一种杂环化合物、其应用及含其的药物组合物
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
US12559487B2 (en) 2019-09-27 2026-02-24 Sumitomo Pharma Co., Ltd. Crosslinked optically active secondary amine derivative
UY38906A (es) 2019-10-09 2021-05-31 Novartis Ag Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos
PH12022550860A1 (en) 2019-10-09 2023-06-14 Novartis Ag 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
UY38988A (es) * 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
JP7454520B2 (ja) * 2020-02-26 2024-03-22 住友ファーマ株式会社 光学活性なアザビシクロ環誘導体からなる医薬
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
IL297039A (en) * 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
EP4232020A4 (en) * 2020-10-21 2024-08-07 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
RU2752079C1 (ru) * 2020-12-01 2021-07-22 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (Е)-(6-(2-гидроксифенил)-2-иминио-4,7,8-триоксо-1,3-дифенил-1,3,6-триазаспиро[4.4]нонан-9-илиден)(4-метоксифенил)метаноат, обладающий противомикробной активностью, и способ его получения
BR112023021040A2 (pt) * 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
EP4334310A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
KR20240006638A (ko) * 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
AU2022274071A1 (en) * 2021-05-11 2024-01-04 Janssen Pharmaceutica Nv Combination therapies
AR125866A1 (es) * 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
CA3218479A1 (en) 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
WO2022253289A1 (en) 2021-06-03 2022-12-08 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
WO2022253309A1 (zh) * 2021-06-03 2022-12-08 首药控股(北京)股份有限公司 取代的杂环化合物及其应用
WO2022257047A1 (en) * 2021-06-09 2022-12-15 Acerand Therapeutics (Hong Kong) Limited Diazaspirobicylic compounds as protein-protein interaction inhibitors and applications thereof
AU2022292697A1 (en) * 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
JP7891524B2 (ja) 2021-08-11 2026-07-16 バイオメア フュージョン,インコーポレイテッド 真性糖尿病に対するメニン-mll相互作用の共有結合性阻害剤
MX2024002189A (es) 2021-08-20 2024-06-11 Biomea Fusion Inc Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimi din-6-il]fenil]-4-[[3(r)-[(1-oxo)-2-propen-1-il)amino]-1-piperidi nil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer.
CN113769098B (zh) * 2021-09-22 2022-09-30 中国医学科学院肿瘤医院深圳医院 MLL-menin抑制剂组合物在制备抗肝癌药物中的应用
EP4271676B1 (en) * 2021-12-03 2026-07-01 Les Laboratoires Servier DIAZASPIRO CARBONYL SUBSTITUTE COMPOUNDS AND THEIR USE
US20250074910A1 (en) * 2021-12-31 2025-03-06 Hitgen Inc. Menin inhibitor and use thereof
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
CN120514709A (zh) * 2022-05-09 2025-08-22 赛达克斯制药股份有限公司 用于治疗癌症的menin-mll抑制剂
CN117069719A (zh) * 2022-08-17 2023-11-17 烨辉医药科技(上海)有限公司 二氮杂螺环-哒嗪化合物及其用途
WO2024046457A1 (en) * 2022-09-02 2024-03-07 Hutchmed Limited Triazine compounds and uses thereof
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
CN118271341A (zh) * 2022-12-30 2024-07-02 成都先导药物开发股份有限公司 Menin抑制剂及其用途
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction
AR132185A1 (es) 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
WO2024213101A1 (zh) * 2023-04-13 2024-10-17 首药控股(北京)股份有限公司 取代的杂环化合物
CN118994033B (zh) * 2023-05-17 2025-09-16 成都先导药物开发股份有限公司 一种sdnx-5613的合成方法及其中间体化合物
CN116969891A (zh) * 2023-07-28 2023-10-31 杭州国瑞生物科技有限公司 一种7-甲基-5-醛基-1h-吲唑的合成方法
IL326799A (en) * 2023-08-28 2026-04-01 Syndax Pharmaceuticals Inc Aryl ether analogs as inhibitors of the menin-mll interaction
WO2025059366A1 (en) * 2023-09-13 2025-03-20 Kumquat Biosciences Inc. Ras inhibitors
WO2025097148A2 (en) 2023-11-04 2025-05-08 Syndax Pharmaceuticals, Inc. Salts and polymorphic forms of menin inhibitors and pharmaceutical compositions thereof
WO2025188611A1 (en) * 2024-03-04 2025-09-12 Dana-Farber Cancer Institute, Inc. Chemical matters for targeting leukemic complex proteins
WO2026098672A1 (zh) * 2024-11-11 2026-05-15 赛诺哈勃药业(成都)有限公司 联氮杂环烷烃类Menin-MLL蛋白抑制剂、其药物组合物及用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5820915A (en) 1996-06-27 1998-10-13 Bioavailability Systems, L.L.C. Method for the preparation of a first-pass effective citrus-derived substance and product thereof
US6124477A (en) 1996-06-27 2000-09-26 Bioavailability Systems, Llc Anti-first-pass effect compounds
US5990154A (en) 1997-05-30 1999-11-23 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds and citrus extract
US6248776B1 (en) 1997-08-26 2001-06-19 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US6063809A (en) 1997-08-26 2000-05-16 Bioavailability Systems, Llc Anti-first-pass effect compounds
US5993887A (en) 1998-06-29 1999-11-30 Bioavailability Systems, L.L.C. Safe citrus juice and process for preparation
JP2001270867A (ja) * 2000-03-23 2001-10-02 Sumitomo Chem Co Ltd フェニルピリダジン化合物
WO2004037827A1 (en) 2000-10-20 2004-05-06 Bioavailability Systems, Llc Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates
JP3592301B2 (ja) * 2002-02-07 2004-11-24 株式会社田窪工業所 簡易建造物の床パネルと側面パネルの接続構造
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2005087728A1 (en) 2004-03-11 2005-09-22 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
AU2005244121B2 (en) 2004-05-07 2012-01-19 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
US20090281114A1 (en) 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型c-kit的方法
ES2750523T3 (es) * 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
US9458124B2 (en) * 2013-02-06 2016-10-04 Wayne State University Substituted pyran derivatives
AU2014249233A1 (en) * 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
EP3290407B1 (en) * 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
US11596636B2 (en) 2014-01-14 2023-03-07 The Trustees Of The University Of Pennsylvania Tailored combinatorial epigenetic therapies for P53 gain-of-function tumors
US20170119769A1 (en) * 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
US20170232030A1 (en) 2014-08-13 2017-08-17 Epizyme, Inc. Combination therapy for treating cancer
CN105732636B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
BR112018012707A2 (pt) 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc inibidores da interação de menin-mll
AU2017212572A1 (en) 2016-01-26 2018-08-23 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
ES2831084T3 (es) * 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
CN118359610A (zh) 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll相互作用のエキソ-アザスピロ阻害剤
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
KR20200136958A (ko) 2018-03-30 2020-12-08 더 리젠츠 오브 더 유니버시티 오브 미시간 공유 메닌 억제제로서의 피페리딘 화합물
AU2019337547A1 (en) 2018-09-13 2021-03-18 Merck Sharp & Dohme Llc Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー,インク. メニン阻害剤を用いた血液悪性腫瘍の処置
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
JP2024520900A (ja) 2021-05-12 2024-05-27 シンダックス ファーマシューティカルズ, インコーポレイテッド 癌の治療のための組合せ
AR125866A1 (es) 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
JP7891524B2 (ja) 2021-08-11 2026-07-16 バイオメア フュージョン,インコーポレイテッド 真性糖尿病に対するメニン-mll相互作用の共有結合性阻害剤
MX2024007201A (es) 2021-12-15 2024-08-06 Dana Farber Cancer Inst Inc Direccionamiento terapeutico del tumor del estroma gastrointestinal (gist) mediante la alteracion del complejo epigenetico de menina-mll.

Similar Documents

Publication Publication Date Title
HRP20201771T1 (hr) Inhibitori interakcije menin-mll
JP2022189853A5 (enExample)
JP7129420B2 (ja) Hpk1阻害剤としてのイソキノリン
WO2021149817A1 (en) Enhancement of anti-tumor activity of SHP2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers
JP2024532733A (ja) 複素環式化合物及び使用方法
JP7460644B2 (ja) Hpk1阻害剤としての置換6-アザベンゾイミダゾール化合物
DK2168966T3 (en) BICYCLOANILIN DERIVATIVES
EP2213673B1 (en) Pyridone-substituted-dihydropyrazolopyrimidinone derivative
CN110621316B (zh) 用ehmt2抑制剂进行的组合疗法
JP7198811B2 (ja) Rsv阻害剤としての組み合わせ医薬剤
RU2018126774A (ru) Ингибиторы менин-mll взаимодействия
JP2013500975A5 (enExample)
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
JP2022500402A5 (enExample)
JP2015511245A5 (enExample)
WO2013026914A1 (en) Serine/threonine pak1 inhibitors
CN111417394B (zh) 苯并咪唑衍生物及其用途
JP2012518598A (ja) ピリミドピリミドインダゾール誘導体
JP2024511841A5 (enExample)
JP2023519362A5 (enExample)
CA3181922C (en) Cd73 inhibiting 2,4-dioxopyrimidine compounds
WO2026080794A1 (en) Chemical compounds useful for degrading proteins
TH2101000346A (th) สารประกอบเฮเทอโรไบไซคลิคสำหรับยับยั้งแอคทิวิทีของ shp2
CN117897159A (zh) 杂环化合物及使用方法
EA052098B1 (ru) Соединения карболина и их применение